Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates, Vol. 01, Jan. 14, 2026
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies
Editor's Note: In 2026, the Qiming Weekly has been upgraded and refreshed, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthroughs.
Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in marking the milestone moments of our portfolio companies.
Funding News
BrightOcular Medical Completes Nearly RMB 100 Million Series A Round
Recently, BrightOcular Medical, a Qiming Venture Partners portfolio company and innovative medical device enterprise focused on minimally invasive precision treatments for ophthalmology, officially announced the completion of a nearly RMB 100 million Series A financing round. The proceeds will be primarily used for clinical follow-up and registration filings for core products, building an industrial production base, establishing a marketing team, and R&D expansion for subsequent product pipelines.
Founded in 2020 by Peking University PhD Kan Min together with leading ophthalmology experts, BrightOcular Medical is a national high-tech enterprise dedicated to building a world-leading platform for original innovative minimally invasive ophthalmic treatments. With "medical-engineering integration, clinically driven" as its core philosophy, the company focuses on the minimally invasive glaucoma surgery (MIGS) field and has built comprehensive solution capabilities covering consumables, instruments, and surgical equipment, aiming to drive China's high-end ophthalmic devices from "following" to "keeping pace" and even "leading."
Dr. Kan Min, Founder and CEO of BrightOcular Medical, stated: "Our original intention in founding BrightOcular Medical was to use original technology to develop minimally invasive products truly suited for Chinese ophthalmic patients, meeting their unmet needs. In recent years, we have completed the technical validation from zero to one; this financing round will help us advance toward the industrialization journey from one to one hundred. We will consistently adhere to the 'medical-engineering integration, clinically grounded' R&D path, giving Chinese doctors their own high-end ophthalmic surgical tools and enabling more patients to receive safe and effective minimally invasive treatment."
Major Partnerships
01/ Insilico Medicine Announces USD 888 Million Anti-Tumor Drug R&D Collaboration with Servier
Recently, Insilico Medicine (03696.HK), a Qiming Venture Partners portfolio company and global leading AI-driven drug discovery company, announced a multi-year R&D collaboration with Servier, a globally independent pharmaceutical company managed by a foundation. The partnership will leverage Insilico Medicine's self-developed AI platform Pharma.AI to identify and develop novel therapeutics targeting challenging targets in the oncology field.
Under the agreement, Insilico Medicine will be eligible to receive up to USD 32 million in upfront and near-term R&D milestone payments, and will lead the discovery and development of potential candidate drugs meeting established criteria using its AI technology platform; Servier will co-fund R&D costs and lead subsequent clinical validation and commercialization.
Christophe Thurieau, Executive Director of Servier Research Institute, stated: "This collaboration demonstrates Servier's commitment to using cutting-edge technology to address unmet medical needs and ultimately benefit patients. It also reflects our confidence in Insilico Medicine's self-developed and validated AI platform."
Dr. Alex Zhavoronkov, Founder, CEO and Chief Business Officer of Insilico Medicine, stated: "I am very excited about this collaboration, which shows that our AI drug discovery capabilities and strengths have once again been recognized. As we integrate generative AI more deeply into every stage of drug discovery, I believe the future of pharmaceutical superintelligence is near — where AI agents can truly make decisions and design experiments, creating a virtuous cycle that drives drug discovery to be faster, smarter, and safer."
02/ Roborock Partners with Real Madrid
Recently, Roborock (688169.SH), a Qiming Venture Partners portfolio company and global leader in home robotics, officially announced a global strategic partnership with the men's and women's first teams of world-class football club Real Madrid C.F. Roborock becomes Real Madrid's global official partner in the cleaning robot and handheld vacuum cleaner categories, launching a long-term strategic collaboration under the theme "Ultimate Experience, Within Reach."
From January 6-9, 2026, both parties jointly appeared at CES in Las Vegas, launching their first co-branded experience event. Consumers and business partners could experience the innovative showcase area co-created by both brands, feeling the new experience brought by the fusion of technology and top-tier sports spirit.
Quan Gang, President of Roborock, and Emilio Butragueño, Director of Institutional Relations at Real Madrid, witnessed the signing together in Madrid. This partnership not only confirms the deep alignment of both brands' philosophies but also stems from their shared innovative core — it is this commitment to innovation that has enabled both parties to achieve outstanding success in their respective fields.
03/ Zhipu AI and DiDi Reach Strategic Partnership
Recently, Zhipu AI (02513.HK), a Qiming Venture Partners portfolio company, and DiDi announced a strategic partnership. Both parties will conduct forward-looking collaborative exploration around key AGI technologies and their intelligent agent applications in the mobility sector.
In recent years, DiDi has continued to increase technical investment in large models and intelligent agents, gradually advancing innovative applications such as AI travel assistants and business travel assistants based on real-world complex mobility scenarios. Zhipu AI has deep accumulation in large model architecture, training paradigms, and intelligent agent technology. Based on this strategic partnership, both parties will jointly promote intelligent agent scenario deployment and large model talent cultivation, deepen intent alignment and reasoning capability building for mobility scenarios, and drive validation and deployment of agents in more complex business scenarios. A DiDi representative stated that both parties look forward to fully leveraging their respective advantages to jointly promote the application and development of AGI in broader real-world scenarios.
04/ Hesai Technology's Full Product Line Global Expansion and Major Partnerships
Recently, Hesai Technology (NASDAQ: HSAI, 02525.HK), a Qiming Venture Partners portfolio company, officially debuted at CES 2026 in Las Vegas. This year, Hesai not only showcased its latest LiDAR technology achievements covering ADAS and robotics, but also announced major partnerships including with NVIDIA, doubling annual production capacity to 4 million units, and steady progress on its Bangkok, Thailand factory — core breakthroughs in global production capacity layout, leading industry development through the synergistic advantages of technology, capacity, and ecosystem.
As highlights of this year's booth, Hesai Technology brought multiple core product upgrades and innovative solutions: including the recently majorly updated ATX refreshed LiDAR equipped with Fermi C500 chip and photon isolation technology; a full series of solutions for next-generation L3-grade automotive applications, covering long-range LiDAR ETX and short-range blind-spot LiDAR FTX; and the mini high-performance 3D LiDAR JT series specially designed for the robotics field, among other star products, comprehensively demonstrating Hesai Technology's technical accumulation and innovative strength in LiDAR.
Among these, the Hesai Technology ATX refreshed version is the most market-anticipated LiDAR, with orders exceeding 4 million units from multiple global top-tier OEMs, with mass production delivery starting in April 2026. The robotics LiDAR Hesai Technology JT series, launched only one year ago, has already surpassed 200,000 units in deliveries. In response to surging global market demand, Hesai Technology announced major capacity plans at CES 2026: annual production capacity will increase from 2 million units in 2025 to 4 million units in 2026, achieving a doubling. Behind this target is Hesai Technology's validated "million-unit annual" mass production delivery capability — as the world's first company to exceed 1 million units in annual production and surpass 2 million units in cumulative deliveries, Hesai Technology completed its 1 millionth unit production milestone in September 2025, and cumulative deliveries exceeded 2 million units in November 2025. Hesai Technology has doubled annual deliveries for five consecutive years, with over 1.6 million units delivered in 2025, and total cumulative deliveries across all LiDAR product lines exceeding 2.4 million units.
05/ MediLink Therapeutics and Roche Sign Another Exclusive License Agreement
Recently, MediLink Therapeutics, a Qiming Venture Partners portfolio company, announced that it has reached a new exclusive license agreement with Roche for the YL201 project, to jointly advance the development and commercialization of this B7H3-targeting innovative antibody-drug conjugate (ADC) candidate in multiple solid tumor indications.
Under the agreement terms, MediLink Therapeutics will grant Roche exclusive rights to develop, manufacture, and commercialize the YL201 project globally (excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region). MediLink Therapeutics will receive USD 570 million in upfront and near-term milestone payments, and is eligible for additional development, registration, and commercialization milestone payments, as well as tiered royalties based on net sales after YL201's overseas approval.
This exclusive license agreement for the YL201 project builds upon the successful collaboration initiated between both parties in January 2024 for the YL211 (c-Met ADC) project. MediLink Therapeutics and Roche will further deepen cooperation to jointly advance the YL201 project. Through this collaboration, both parties will fully leverage their respective advantages to accelerate the global registration filing process for YL201. Based on their shared commitment to scientific innovation and patient welfare, MediLink Therapeutics and Roche are dedicated to bringing this potentially innovative therapy to patients as early as possible.
R&D Progress
01/
GenEditBio's GEB-101 Receives FDA Clinical Trial Approval
*Recently, GenEditBio, a Qiming Venture Partners portfolio company and clinical-stage biotechnology innovator, announced that its self-developed in vivo genome editing investigational drug **GEB-101 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). The company will officially launch in the United States the Phase I/II clinical trial abbreviated as "CLARITY," aiming to bring "one-time cure" *hope to patients with TGFBI-related corneal dystrophy.
The CLARITY clinical trial is an adaptive, seamlessly designed Phase I/II multicenter study using sequential enrollment, aiming to collect preliminary data to evaluate the safety, tolerability, and efficacy of GEB-101 in patients with TGFBI-related corneal dystrophy. Subjects will receive a single intrastromal corneal injection, with enrollment expected to begin progressively at U.S. research centers starting in the second quarter of this year.
Dr. Zhengli Zheng, Chairman and Co-founder of GenEditBio, stated: "GEB-101 receiving FDA IND approval is a major milestone for GenEditBio. This marks a critical step forward in our mission to provide patients worldwide with innovative in vivo genome editing therapies based on ribonucleoprotein (RNP) gene editing and delivery technology, featuring 'ready-to-use and rapid degradation' characteristics, to achieve efficient target tissue editing with low off-target risk. This achievement reflects the rigorous, professional, and efficient efforts of the entire team, demonstrating our capability to rapidly advance frontier basic research to the clinical stage."
02/
ArkBio Announces Compound Dexmethylphenidate Hydrochloride and Serdexmethylphenidate Capsules (Aizhida®) Approved in China for ADHD Treatment
Recently, ArkBio, a Qiming Venture Partners portfolio company, announced that the National Medical Products Administration (NMPA) has approved the new drug application for compound dexmethylphenidate hydrochloride and serdexmethylphenidate capsules (Aizhida®), indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older.
Aizhida® is an ADHD treatment drug with an innovative mechanism, and is the world's first and currently only combination formulation containing immediate-release dexmethylphenidate (d-MPH) and prodrug serdexmethylphenidate (SDX). By modulating brain neurotransmitters associated with ADHD, it provides patients with a treatment option featuring both rapid onset and long-acting effects. The drug was approved in the United States in March 2021, becoming the first new-generation methylphenidate drug approved by the FDA in nearly two decades, with clear advantages in safety and therapeutic mechanism.
Technology Strength
01/
Zhipu AI Participates in Malaysia's Sovereign AI Development
Recently, Malaysia's national MaaS platform and national sovereign AI talent cultivation laboratory Z·UM AI Lab was launched and became operational. The national MaaS platform is built on the open-source foundation model of Zhipu AI's Z.ai (02513.HK), a Qiming Venture Partners portfolio company, and optimized for Malaysia's multilingual environment (Malay, English, Chinese) and local culture, thereby providing powerful reasoning, coding, and agent capabilities while maintaining sovereignty-centered data security architecture and national-level AI platform autonomy, empowering government, enterprise, scientific research, and student education scenarios.
As the first Chinese company to achieve substantive deployment of a national-level sovereign large model overseas, Zhipu AI is also one of the few large model enterprises capable of completing the full chain from model deployment, platform-based services to ecosystem building in national scenarios. Going forward, Zhipu AI will continue to actively respond to "AI+" global cooperation, treating large models as international public goods for the benefit of humanity, and building more national AI infrastructure.
02/
WeRide Appears in NVIDIA's Autonomous Driving Ecosystem
Recently, WeRide (NASDAQ: WRD, 00800.HK), a Qiming Venture Partners portfolio company and global leading autonomous driving technology company, announced that as an NVIDIA global L4-level Robotaxi ecosystem partner, its Robotaxi GXR became the world's first Robotaxi equipped with the NVIDIA DRIVE Thor chip, already achieving pure unmanned commercial operations in China and the UAE.
As an important partner in NVIDIA's global L4 autonomous driving and Robotaxi ecosystem, WeRide continues to lead at the industry forefront. It is not only the world's only technology company to achieve scaled commercial application of both L4 unmanned driving and L2+ advanced driver assistance, but has also officially announced the application of L2+ advanced driver assistance's one-stage end-to-end technology in L4 unmanned driving R&D and commercial operations, becoming the world's first autonomous driving technology company to integrate the Tesla approach and the Waymo approach. This industry-leading position stems from WeRide's general autonomous driving technology platform — WeRide One — built with L4 Robotaxi technology at its core. The platform takes full-stack autonomous driving software algorithms as its core, systematically integrating AI models, software algorithms, modular hardware design, and cloud architecture platforms, with high generality and scalability, capable of efficiently empowering different vehicle models with batch deployment of autonomous driving capabilities in urban scenarios, achieving "one platform, connecting countless scenarios."
Past Reviews
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching USD 9.5 billion. Since its establishment, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, among others.